Asset Details
Do you wish to reserve the book?
The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study – 6 month results
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study – 6 month results
Do you wish to request the book?
The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study – 6 month results
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study – 6 month results
2023
Overview
Background/Objective
Investigate real-world patients receiving faricimab for the treatment of neovascular age-related macular degeneration (nAMD).
Subjects/Methods
Multicenter, retrospective chart review was conducted on patients treated with faricimab for nAMD from February 2022 to September 2022. Collected data includes background demographics, treatment history, best-corrected visual acuity (BCVA), anatomic changes, and adverse events as safety markers. The main outcome measures are changes in BCVA, changes in central subfield thickness (CST) and adverse events. Secondary outcome measures included treatment intervals and presence of retinal fluid.
Results
After one injection of faricimab, all eyes (
n
= 376), previously-treated (
n
= 337) and treatment-naïve (
n
= 39) eyes demonstrated a + 1.1 letter (
p
= 0.035), a + 0.7 letter (
p
= 0.196) and a + 4.9 letter (
p
= 0.076) improvement in BCVA, respectively, and a − 31.3 μM (
p
< 0.001), a − 25.3 μM (
p
< 0.001) and a − 84.5 μM (
p
< 0.001) reduction in CST, respectively. After three injections of faricimab, all eyes (
n
= 94), previously-treated (
n
= 81) and treatment-naïve (
n
= 13) eyes demonstrated a + 3.4 letter (
p
= 0.03), a + 2.7 letter (
p
= 0.045) and a + 8.1 letter (
p
= 0.437) improvement in BCVA, and a − 43.4 μM (
p
< 0.001), a − 38.1 μM (
p
< 0.001) and a − 80.1 μM (
p
< 0.204) reduction in CST, respectively. One case of intraocular inflammation was observed after four injections of faricimab and resolved with topical steroids. One case of infectious endophthalmitis was treated with intravitreal antibiotics and resolved.
Conclusions
Faricimab has demonstrated improvement or maintenance of visual acuity for patients with nAMD, along with rapid improvement of anatomical parameters. It has been well-tolerated with low incidence of treatable intraocular inflammation. Future data will continue to investigate faricimab for real-world patients with nAMD.
Publisher
Nature Publishing Group UK,Nature Publishing Group
